Research Aspects and Strategies for the Development of Biosensors for Renal Disease Diagnosis

Srivastava, Akshay; Agarwal, Gopal

doi:10.1007/978-981-16-2782-8_7

Cited by 2 publications

(7 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a microfluidic-based immunoassay (cassette = $15) where readout is performed using a Claros1 Analyzer (∼$2500) in 12 min. The test can quantitatively determine PSA levels ranging from 0.08 to 15 ng/mL, but the sensitivity (85.4%) and specificity (30.3%) are limited. ,, The i-CHROMA (Boditech) utilizes LFAs ($7) and a fluorescent analyzer (∼$2200) for the quantitative determination of PSA across a wide range (0.1–100 ng/mL) in 15 min . The sensitivity/specificity are not provided, but Beltan et al showed a good correlation (r 2 = 0.9664) with another commercial PSA test (Elecsys PSA Test – Roche Diagnostics)…”

Section: Emerging Point-of-care Testsmentioning

confidence: 99%

“…111 , 112 , 115 The i-CHROMA (Boditech) utilizes LFAs ($7) and a fluorescent analyzer (∼$2200) for the quantitative determination of PSA across a wide range (0.1–100 ng/mL) in 15 min. 113 The sensitivity/specificity are not provided, but Beltan et al showed a good correlation (r 2 = 0.9664) with another commercial PSA test (Elecsys PSA Test – Roche Diagnostics). 116…”

Section: Emerging Point-of-care Testsmentioning

confidence: 99%

See 1 more Smart Citation

Point-of-Care Prostate Specific Antigen Testing: Examining Translational Progress toward Clinical Implementation

Garg,

Sachdeva,

Peeters

et al. 2023

ACS Sens.

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most common male cancer and is attributable to over 375,000 deaths annually. Prostate specific antigen (PSA) is a key biomarker for PCa and therefore measuring patient PSA levels is an important aspect of the diagnostic pathway. Automated immunoassays are currently utilized for PSA analysis, but they require a laboratory setting with specialized equipment and trained personnel. This results in high diagnostic costs, extended therapeutic turnaround times, and restrictions on testing capabilities in resource-limited settings. Consequently, there is a strong drive to develop point-of-care (PoC) PSA tests that can offer accurate, low-cost, and rapid results at the time and place of the patient. However, many emerging PoC tests experience a trade-off between accuracy, affordability, and accessibility which distinctly limits their translational potential. This review comprehensively assesses the translational advantages and limitations of emerging laboratory-level and commercial PoC tests for PSA determination. Electrochemical and optical PSA sensors from 2013 to 2023 are systematically examined. Furthermore, we suggest how the translational potential of emerging tests can be optimized to achieve clinical implementation and thus improve PCa diagnosis globally.

show abstract

Section: Emerging Point-of-care Testsmentioning

confidence: 99%

Section: Emerging Point-of-care Testsmentioning

confidence: 99%

Point-of-Care Prostate Specific Antigen Testing: Examining Translational Progress toward Clinical Implementation

Garg,

Sachdeva,

Peeters

et al. 2023

ACS Sens.

View full text Add to dashboard Cite

show abstract

“…Currently, there are only two PoC multianalyte quantification devices in clinical use, the Abbott i-Stat® and the Siemen's Epoc®. Both PoC devices leverage labelled processes analyzing blood samples using electrochemical biosensors (ECBs) [11], [12]. ECBs perform biosensing by transduce biomarkers to an electrical signal through labelled enzyme catalysis reactions.…”

Section: List Of Figuresmentioning

confidence: 99%

“…500µm of TIPS-pentacene, 120 nm of PVA and 190 nm of Sylgard 184 PDMS (10:1 elastomer to curing agent) are spin deposited. The PDMS is left uncured for the final integration step [12].…”

Section: Oegfet Aptasensormentioning

confidence: 99%

“…Current -voltage (I-V) sweeps were performed by keeping a constant source drain voltage (V SD ) of 3V and sweeping the source gate voltage (V SG ) from 0 -6 V in increments of 12.5 mV with a settling time of 500 ms. The voltage range was established in our previously published OEGFET aptasensor works [12]. Source current (I SD ) and leakage current (I GS ) data were collected for each test.…”

Section: Mip Eis Biosensormentioning

confidence: 99%

See 1 more Smart Citation

Next Generation Non-Invasive Biomarker Testing in Saliva: The Organic Electrolyte Gated Field Effect Transistor Aptasensor System

Massey

View full text Add to dashboard Cite

Diagnostic biomolecule quantification in healthcare relies on effective but centralized laboratory testing procedures. However, as the need for testing rapidly grows, the current process is struggling to meet the demand. Rapid point-of-contact analysis devices are not capable of non-invasive quantification of small, dilute molecules such as steroid hormones in saliva. Current literature bioquantification devices suffer from drawbacks such as short shelf life, high intra-device variability, sample matrix effects, material incompatibilities, high-cost fabrication and data collection that rely on laboratory conditions and processes. This body of work took our organic electrolyte gated field effect transistor (OEGFET), a novel biosensor architecture, and developed it into a feasible platform for real-world biomolecule quantification applications.1-iv | P a g e For all of the papers presented in this work I was listed as the primary author as I contributed to study conception and design, device fabrication, device testing, analysis and interpretation of results, and manuscript draft preparation. My supervisor Prof. R. Prakash contributed to study conception and design, result interpretation, and manuscript preparation for all papers.Additional Contributions: J1. Dr. S. Bebe fabricated the top gate surfaces and helped with editing the manuscript draft. J2. Dr. R. Amache developed the bio-gel fabrication process, fabricated the bio-gel EDLC capacitors and helped with manuscript editing. Dr. S. Bebe also helped with manuscript preparation and fabricated the device top gates. J3. I also redesigned the OEGFET devices into a flexible format including establishing an APTES immobilization process that would be suitable for Kapton and safe to perform in our cleanroom. J4. I also optimized the new models and designed their parameter extraction processes. J5. I also redesigned the APTES process to prevent delamination. Prof. R. Prakash also acquired ethics board approval for the collection and testing of human saliva. J6. B. Gamero and I decided on the current shunt method of data collection for the OEGFET, and I wrote the software for the OEGFET data collection with the board. B. Gamero designed the footprint, EIS collection method, and external circuitry of the printed circuit board. J7. We used the same board developed by B. Gamero from J6. J8. We used the same board developed by B. Gamero from J6. J9. I designed the PVA-Carrageenan cross linking on surface process based on the bulk crosslinking work of Dr. R. Amache, transistor device testing, analysis and interpretation of results, and manuscript draft preparation. X. Song performed capacitor fabrication, capacitor data collection and analysis, and contributed to manuscript preparation. J10. Dr. E. McConnell and Prof. M. DeRosa of the Ladder group at Carleton designed and produced the αSyn aptamer and contributed to manuscript preparation. D. Chan and Prof. M. Holahan performed the fluorescence quantification and contributed to manuscript preparation. Additional contributio...

show abstract

Research Aspects and Strategies for the Development of Biosensors for Renal Disease Diagnosis

Cited by 2 publications

References 59 publications

Point-of-Care Prostate Specific Antigen Testing: Examining Translational Progress toward Clinical Implementation

Point-of-Care Prostate Specific Antigen Testing: Examining Translational Progress toward Clinical Implementation

Next Generation Non-Invasive Biomarker Testing in Saliva: The Organic Electrolyte Gated Field Effect Transistor Aptasensor System

Contact Info

Product

Resources

About